References
- 1Khan A, Sergi C. Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder. Diagn Basel Switz. 2018 Apr 25; 8(2): E29. DOI: 10.3390/diagnostics8020029
- 2Fuller M, Meikle PJ, Hopwood JJ.
Epidemiology of lysosomal storage diseases: an overview . In: Mehta A, Beck M, Sunder-Plassmann G (eds.). Fabry Disease: Perspectives from 5 Years of FOS [Internet]. Oxford: Oxford PharmaGenesis; 2006 [cited 2021 Jul 24]. Available from:http://www.ncbi.nlm.nih.gov/books/NBK11603/ . - 3Rapin I. Myoclonus in neuronal storage and Lafora diseases. Adv Neurol. 1986; 43: 65–85.
- 4Ahn JH, Kim AR, Lee C, Kim NKD, Kim N-S, Park W-Y, et al. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review. Cerebellum Lond Engl. 2019 Jun; 18(3): 659–64. DOI: 10.1007/s12311-019-1005-2
- 5Franceschetti S, Canafoglia L. Sialidoses. Epileptic Disord Int Epilepsy J Videotape. 2016 Sep 1; 18(S2): 89–93. DOI: 10.1684/epd.2016.0845
- 6Nirenberg MJ, Frucht SJ. Myoclonus. Curr Treat Options Neurol. 2005 May; 7(3): 221–30. DOI: 10.1007/s11940-005-0015-1
- 7Rumbach AF, Blitzer A, Frucht SJ, Simonyan K. An open-label study of sodium oxybate in Spasmodic dysphonia. The Laryngoscope. 2017 Jun; 127(6): 1402–7. DOI: 10.1002/lary.26381
- 8Riboldi GM, Frucht SJ. Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance-Adams Syndrome. Tremor Hyperkinetic Mov N Y N. 2019; 9. DOI: 10.5334/tohm.472
- 9Frucht SJ, Riboldi GM. Alcohol-Responsive Hyperkinetic Movement Disorders-a Mechanistic Hypothesis. Tremor Hyperkinetic Mov N Y N. 2020 Oct 21; 10: 47. DOI: 10.5334/tohm.560
- 10Priori A, Bertolasi L, Pesenti A, Cappellari A, Barbieri S. gamma-hydroxybutyric acid for alcohol-sensitive myoclonus with dystonia. Neurology. 2000 Apr 25; 54(8): 1706. DOI: 10.1212/WNL.54.8.1706
- 11Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord Off J Mov Disord Soc. 2005 Oct; 20(10): 1330–7. DOI: 10.1002/mds.20605
- 12Canafoglia L, Franceschetti S, Uziel G, Ciano C, Scaioli V, Guerrini R, et al. Characterization of severe action myoclonus in sialidoses. Epilepsy Res. 2011 Mar; 94(1–2): 86–93. DOI: 10.1016/j.eplepsyres.2011.01.013
- 13Steinman L, Tharp BR, Dorfman LJ, Forno LS, Sogg RL, Kelts KA, et al. Peripheral neuropathy in the cherry-red spot-myoclonus syndrome (sialidosis type I). Ann Neurol. 1980 May; 7(5): 450–6. DOI: 10.1002/ana.410070510
- 14Mütze U, Bürger F, Hoffmann J, Tegetmeyer H, Heichel J, Nickel P, et al. Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in NEU1 gene causing sialidosis type I associated with mild to unspecific biochemical and enzymatic findings. Mol Genet Metab Rep. 2017 Mar; 10: 1–4. DOI: 10.1016/j.ymgmr.2016.11.004
- 15Sobral I, Cachulo M da L, Figueira J, Silva R. Sialidosis type I: ophthalmological findings. BMJ Case Rep. 2014 Oct 16; 2014: bcr2014205871. DOI: 10.1136/bcr-2014-205871
- 16Daich Varela M, Zein WM, Toro C, Groden C, Johnston J, Huryn LA, et al. A sialidosis type I cohort and a quantitative approach to multimodal ophthalmic imaging of the macular cherry-red spot. Br J Ophthalmol. 2021 Jun; 105(6): 838–43.
- 17Panzica F, Canafoglia L, Franceschetti S, Binelli S, Ciano C, Visani E, et al. Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG-EMG relationship estimated using autoregressive models. Clin Neurophysiol Off J Int Fed Clin Neurophysiol. 2003 Jun; 114(6): 1041–52. DOI: 10.1016/S1388-2457(03)00066-X
- 18Leavitt JA, Kotagal S. The “cherry red” spot. Pediatr Neurol. 2007 Jul; 37(1): 74–5. DOI: 10.1016/j.pediatrneurol.2007.04.011
- 19Lewis RF, Traish AS, Lessell S. Atypical voluntary nystagmus. Neurology. 2009 Feb 3; 72(5): 467–9. DOI: 10.1212/01.wnl.0000341876.76523.99
- 20Pritchard C, Flynn JT, Smith JL. Wave form characteristics of vertical oscillations in longstanding vision loss. J Pediatr Ophthalmol Strabismus. 1988 Oct; 25(5): 233–6. DOI: 10.3928/0191-3913-19880901-08